Zoetis' Acquisition of Neogen Genomics Business Faces Regulatory Scrutiny in Australia - Zoetis (NYSE:ZTS

The Australian agency is conducting a Phase 2 assessment of Zoetis' $160 million acquisition of Neogen's genomics unit due to competition concerns.

Raccontata dabenzinga.com